Amsterdam UMC, University of Amsterdam, Laboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam, The Netherlands.
Amsterdam UMC, University of Amsterdam, Laboratory of Viral Immune Pathogenesis, Department of Experimental Immunology, Amsterdam, The Netherlands.
mBio. 2021 Mar 9;12(2):e00099-21. doi: 10.1128/mBio.00099-21.
Incomplete restoration of CD4 T-cell counts on antiretroviral therapy (ART) is a major predictor of HIV-related morbidity and mortality. To understand the possible mechanisms behind this poor immunological response despite viral suppression, we longitudinally measured more than 50 virological and immunological biomarkers in a cohort of HIV-infected individuals at several time points during the first 96 weeks of virologically suppressive ART. No baseline virological or immunological marker was predictive of the degree of immune reconstitution. However, the cell-associated HIV-1 unspliced-to-multiply-spliced (US/MS) RNA ratio at 12 weeks of ART positively correlated with markers of CD4 T-cell activation and apoptosis and negatively predicted both the absolute and relative CD4 T-cell counts at 48 and 96 weeks. A higher US/MS RNA ratio may reflect the higher frequency of productively infected cells that could exert pressure on the immune system, contributing to persistent immune activation and apoptosis and subsequently to a poor immunological response to ART. Human immunodeficiency virus (HIV) infection is currently managed by antiretroviral drugs, which block virus replication and promote immune restoration. However, the latter effect is not universal, with a proportion of infected individuals failing to sufficiently reconstitute their immune function despite a successful virological response to antiretroviral therapy (ART). No reliable predictive markers of immunological failure have been identified, and there is still no efficient therapeutic strategy, apart from ART itself, to facilitate immune reconstitution. Here, we measured more than 50 viral and host biomarkers at five time points during the first 2 years of ART and identified the cell-associated HIV-1 unspliced-to-multiply-spliced RNA ratio at 12 weeks of ART as a predictive factor for the immunological response to therapy. Moreover, the same marker positively correlated with markers of CD4 T-cell activation and apoptosis. The fact that a virological biomarker performed better than any immunological biomarker in predicting an immunological outcome highlights the importance of considering the residual HIV activity on ART as a correlate and a possible cause of the residual immune dysfunction that frequently occurs despite virologically suppressive ART.
在抗逆转录病毒治疗(ART)中,CD4 T 细胞计数不完全恢复是与 HIV 相关发病率和死亡率的主要预测因素。为了了解尽管病毒得到抑制但免疫反应仍较差的可能机制,我们在接受抑制病毒的 ART 治疗的最初 96 周内的多个时间点,对 HIV 感染者队列进行了超过 50 项病毒学和免疫学标志物的纵向测量。没有基线病毒学或免疫学标志物可以预测免疫重建的程度。然而,ART 治疗 12 周时细胞相关 HIV-1 未剪接-多剪接(US/MS)RNA 比值与 CD4 T 细胞活化和凋亡标志物呈正相关,与 48 周和 96 周时的绝对和相对 CD4 T 细胞计数呈负相关。较高的 US/MS RNA 比值可能反映了更频繁的具有感染性的细胞,这些细胞可能对免疫系统施加压力,导致持续的免疫激活和凋亡,随后对 ART 的免疫反应较差。人类免疫缺陷病毒(HIV)感染目前通过抗逆转录病毒药物进行管理,这些药物可阻断病毒复制并促进免疫恢复。然而,尽管对 ART 有成功的病毒学反应,但并非所有受感染的个体都能充分重建其免疫功能,这一效果并非普遍存在。尚未确定免疫失败的可靠预测标志物,除了 ART 本身之外,仍然没有有效的治疗策略来促进免疫重建。在这里,我们在 ART 治疗的最初 2 年内的五个时间点测量了超过 50 项病毒和宿主标志物,并确定了 ART 治疗 12 周时细胞相关 HIV-1 未剪接-多剪接 RNA 比值作为治疗免疫反应的预测因素。此外,相同的标志物与 CD4 T 细胞活化和凋亡标志物呈正相关。在预测免疫结果方面,病毒学标志物比任何免疫学标志物表现更好,这一事实强调了考虑 ART 时残留 HIV 活性作为相关性以及可能导致尽管病毒抑制性 ART 仍经常发生的残留免疫功能障碍的原因的重要性。
J Infect Public Health. 2017-8-18
Front Cell Infect Microbiol. 2024
Front Immunol. 2024-12-26
BMC Public Health. 2023-9-16
Front Microbiol. 2023-8-7
J Antimicrob Chemother. 2018-7-1